138 related articles for article (PubMed ID: 21155943)
1. Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study).
Verpooten GA; Aerts A; Coen N; Vancayzeele S; Hermans C; Bowles J; MacDonald K; Abraham I; Lee CS
Int J Clin Pract; 2011 Jan; 65(1):54-63. PubMed ID: 21155943
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study).
Lins R; Aerts A; Coen N; Hermans C; MacDonald K; Brié H; Lee C; Shen YM; Vancayzeele S; Mecum N; Abraham I
Ann Pharmacother; 2011 Jun; 45(6):727-39. PubMed ID: 21666094
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
Van der Niepen P; Woestenburg A; Brié H; Vancayzeele S; MacDonald K; Denhaerynck K; Lee C; Hermans C; Abraham I
Ann Pharmacother; 2009 May; 43(5):849-61. PubMed ID: 19351876
[TBL] [Abstract][Full Text] [Related]
5. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
6. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
[TBL] [Abstract][Full Text] [Related]
7. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
8. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS).
Volman S; Benitez FN; Cedenio H; Giorgi M; Jaramillo N; Molina N; Zilberman J
Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):189-96. PubMed ID: 23723254
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
Zhu JR; Sun NL; Yang K; Hu J; Xu G; Hong H; Wang R; Tu YM; Ritter S; Keefe D;
Hypertens Res; 2012 Jan; 35(1):28-33. PubMed ID: 21900941
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
Minerva Cardioangiol; 2013 Aug; 61(4):461-9. PubMed ID: 23846012
[TBL] [Abstract][Full Text] [Related]
12. Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.
Lins R; Coen N; Aerts A; Macdonald K; Brié H; Hermans C; Shen YM; Lee C; Vancayzeele S; Mecum N; Abraham I
Arch Cardiovasc Dis; 2011 Aug; 104(8-9):428-34. PubMed ID: 21944144
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.
Gradman AH; Weir MR; Wright M; Bush CA; Keefe DL
J Hum Hypertens; 2010 Nov; 24(11):721-9. PubMed ID: 20200550
[TBL] [Abstract][Full Text] [Related]
14. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Bush C; Keefe DL
J Hypertens; 2009 Jul; 27(7):1493-501. PubMed ID: 19444142
[TBL] [Abstract][Full Text] [Related]
17. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.
Duprez DA; Munger MA; Botha J; Keefe DL; Charney AN
J Hum Hypertens; 2010 Sep; 24(9):600-8. PubMed ID: 20033075
[TBL] [Abstract][Full Text] [Related]
19. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
